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ABSTRACT
Urinary magnesium and pH are known to modulate urinary calcium excretion, but the mechanisms
underlying these relationships are unknown. In this study, the data from 17 clinical trials in which urinary
magnesium and pH were pharmacologically manipulated were analyzed, and it was found that the
change in urinary calcium excretion is directly proportional to the change in magnesium excretion and
inversely proportional to the change in urine pH; a regression equation was generated to relate these
variables (R2  0.58). For further exploration of these relationships, intravenous calcium chloride,
magnesium chloride, or vehicle was administered to rats. Magnesium infusion significantly increased
urinary calcium excretion (normalized to urinary creatinine), but calcium infusion did not affect magne-
sium excretion. Parathyroidectomy did not prevent this magnesium-induced hypercalciuria. The effect of
magnesium loading on calciuria was still observed after treatment with furosemide, which disrupts
calcium and magnesium absorption in the thick ascending limb, suggesting that the effect may be
mediated by the distal nephron. The calcium channel TRPV5, normally present in the distal tubule, was
expressed in Xenopus oocytes. Calcium uptake by TRPV5 was directly inhibited by magnesium and low
pH. In summary, these data are compatible with the hypothesis that urinary magnesium directly inhibits
renal calcium absorption, which can be negated by high luminal pH, and that this regulation likely takes
place in the distal tubule.
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The amount of calcium excreted in the urine (cal-
ciuria) is tightly regulated by a complex interaction
between numerous calcitropic hormones, extracel-
lular volume, acid-base status, and plasma and uri-
nary concentration of various ions.1 Calciuria is a
continuous trait in the general population, and hy-
percalciuria is amajor risk factor for nephrolithiasis
found in high incidence in the stone former and/or
in the osteoporotic populations.2
The first description of an effect of magnesium
on calciuria was made in a seminal article by Men-
del and Benedict in 1909.3 They observed increased
calcium excretion and decreased fecal calcium con-
tent whenmagnesium salts were injected to various
animal species. Similar observations were later re-
ported in humans in preeclamptic pregnantwomen
who were treated with magnesium sulfate and in
normal individuals.4,5 This effectwas attributable to
magnesium and not sulfate.6 Attempts have been
made to localize the segment where urinarymagne-
sium could mediate its effect on calcium reabsorp-
tion in different animal models. Metabolic experi-
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ments confirmed that calciuria can be increased by
intravenous magnesium infusion in dogs with normal or re-
duced kidney function,7 but stop-flow experiments did not
precisely identify the segment involved.8,9 Micropuncture ex-
periments in rats infused with magnesium chloride suggested
that the loop of Henle maybe involved.10,11 In sum, these stud-
ies are compatible with the initial observation of Mendel and
Benedict, but the mechanisms by which magnesium increases
calciuria remain largely unknown.
Urinary calcium excretion is increased by metabolic acidosis,
at least in part bydecreasing renal calciumreabsorption.12,13High
dietary animal protein intake decreases urinary pH (by increasing
acid load) and increases calcium excretion.14–16 Conversely, uri-
nary alkalinization by potassium alkali decreases urinary cal-
cium.17,18 Recent studies have found that extra- and intracellular
protons inhibit the renal epithelial apical calcium channels
TRPV5 and TRPV6 within the physiologic urinary and intracel-
lular pH ranges.19–24 These results suggest that acid pH increases
calciuria by inhibiting TRPV5/6-mediated calcium reabsorption
in thedistal nephron. In aheterologous systemusing sodiumcur-
rent as a surrogate, micromolar concentrations of magnesium
have also been shown to inhibit TRPV5.21,25 Here, we report on a
collection of translational studies involving humans, rats, and an
in vitro experiment showing that calciuria is modulated by both
urinary pH andmagnesium.
RESULTS
Human Data
Source.
Retrospective data from the University of Texas Southwestern
Medical CenterNephrolithiasis Registry from17 studies17,26–36
that dealt with physiologic and physicochemical effects of var-
ious magnesium and potassium salts were categorized into
three groups and analyzed. These studies were conducted for a
variety of purposes, but they all involved manipulation of uri-
nary magnesium, pH, or both. Table 1 summarizes the char-
acteristics of these studies. In group 1, participants took mag-
nesium oxide (MgO) or citrate (Mg3Citrate2). Participants in
group 2 took potassium bicarbonate (KHCO3) or citrate
(K3Citrate). Participants in group 3 took potassium magne-
sium citrate (K4MgCitrate2).
Within-Group Comparison of Urinary Magnesium, pH, and
Calcium.
This is summarized in Supplemental Table 1. Urinary mag-
nesium increased significantly during treatment with mag-
nesium salts (groups 1 and 3) but not with potassium alkali
(group 2). The rise in urinary magnesium was more pro-
nounced in group 1 than in group 3, likely as a result of
dosage effect. Urinary pH rose significantly during treat-
ment with potassium alkali (group 2) and potassium-magne-
sium citrate (group 3). The rise in pH was comparable between
groups 2 and 3 but was minimal and insignificant in group 1.
Urinary calcium increased significantly after magnesium ox-
ide/citrate treatment (group 1) and decreased with potassium
alkali treatment (group 2). It displayed a slight and statistically
insignificant increase after potassium-magnesium citrate
treatment (group 3).
Across-Group Comparison of Changes in Urinary Magnesium,
pH, and Calcium.
Changes in urinary magnesium were significantly different
among all three groups (Supplemental Table 1), with no
change in group 2, substantial increase in group 1, and an
intermediate change in group 3. The amplitude of changes in
urinary pH in groups 2 (potassium alkali) and 3 (potassium-
magnesium alkali) were similar and significantly different
from the change encountered in group 1 (magnesium).
Changes in urinary calcium were all different among the three
groups, with an increase in group 1, a decrease in group 2, and
no change in group 3.
Dependence of Urinary Calcium on UrinaryMagnesium and pH.
A summary of this retrospective analysis is depicted in Figure 1
as a three-dimensional plot of changes in urinary calcium as a
function of magnesium and pH. On the basis of the across-
groupunivariate comparisons, the threemain groupswere dis-
tinct from each other. A regression of the change in urinary
calcium on the changes in urinary magnesium and urinary pH
showed that the relationship could be empirically described by
the following equation:
UCa V 0.70 0.26 UMg V 2.06 UpH,
where V stands for the urinary volume. The R2 for the regres-
sion was 0.58.
Table 1. Human data retrieved from the University of Texas Southwestern Medical Center Nephrolithiasis Registry
Parameter
Group
1 2 3
Intervention MgO or Mg3Citrate2 KHCO3 or K3Citrate K4MgCitrate2
No. of trials 4 8 5
Dosage (mEq/d)
Magnesium 46.7 (24.5 to 82.2) 0.0 23.8 (21.0 to 24.5)
Potassium 0 60 (40 to 80) 48 (42 to 49)
Treatment duration (wk) 2.0 (0.9 to 3.0) 2.0 (1.0 to 4.0) 2.6 (1.0 to 3.0)
No. of participant 47 (4 to 21) 89 (5 to 21) 102 (10 to 30)
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Clearance Studies in Rats
Although the human data are compatible and suggestive of
urinary magnesium and pH interaction in controlling calci-
uria, many factors are not controlled in a retrospective analy-
sis. For studying the effect of infused magnesium on urinary
calcium excretion, normal Sprague-Dawley rats were loaded
with 20mol/100 g bodyweightmagnesium chloride (MgCl2)
for 1 h. They responded with the expected increase in their
urinarymagnesium-creatinine ratio (Figure 2A) and also by an
increase of the calcium-creatinine ratio. Calcium infusion
(CaCl2) augmented only calciuria and notmagnesiuria (Figure
2B). Vehicle alone did not cause any significant change in ei-
ther magnesium-creatinine or calcium-creatinine ratio (Fig-
ure 2C).
The plasma magnesium concentration was significantly in-
creased at the end of theMgCl2 perfusion (baseline 2.03 0.23
mg/dl or 0.83  0.09 mmol/L; at the end of 1 h of perfusion
2.93 0.10 mg/dl or 1.20 0.04 mmol/L [P 0.001; n 6];
1 h after the end of the perfusion 1.98 0.08 mg/dl or 0.81
0.03 mmol/L [NS; n  6]). The total calcium concentration
decreased (9.2  0.4 mg/dl or 2.3  0.1 mmol/L at baseline;
8.6 0.4 mg/dl or 2.15 0.01 mmol/L at the end of the 1 h of
perfusion [P 0.001; n 6]), and serum sodium and albumin
did not change (data not shown).
To test whether the increase of calciuria observed in rats
infused with MgCl2 is secondary to a fall in parathyroid
hormone (PTH),37,38 we repeated the same protocol in para-
thyroidectomized (PTX) rats. Calcium-creatinine and mag-
nesium-creatinine ratios were significantly higher at base-
line in PTX rats compared with normal rats (calcium-
creatinine ratio 1.99 1.33 in PTX rats versus 0.87 0.29 in
normal rats [P  0.04; n  4 to 6]; magnesium-creatinine
ratio 2.09  0.61 in PTX rats versus 1.38  0.26 in normal
rats [P  0.01; n  4 to 6]). PTX rats had a significantly
lower plasma calcium concentration, despite calcium sup-
plementation in their drinking water (8.3  0.3 mg/dl or
2.1  0.1 mmol/L versus 9.2  0.4 mg/dl or 2.3  0.1
mmol/L in normal rats [P  0.01; n  3 to 6]); however,
PTX rats still raised their urinary calcium-creatinine ratio
by two- to three-fold when loaded with MgCl2 (Figure 2D).
When infused with CaCl2, the increase of calcium-creati-
nine ratio was smaller compared with PTH-intact rats (Fig-
ure 1F). Vehicle infusion alone did not elicit any change in
either magnesium-creatinine or calcium-creatinine ratio.
These studies show that the magnesium-induced hypercal-
ciuria can occur independent of PTH.
High luminal magnesium can compete with calcium for
paracellular reabsorption in the thick ascending limb. We
next addressed the role of the thick ascending limb in the
magnesium-induced calciuria by disrupting calcium and
magnesium absorption with furosemide in this segment. To
prevent volume contraction, we preloaded the rats intra-
peritoneally with 3 ml/100 g body weight 0.45% saline. We
Figure 1. Three-dimensional representation of the simulta-
neous effect of various treatments on urinary pH, magnesiuria,
and calciuria. Studies involving treatment by magnesium oxide
or citrate (gray circles), potassium bicarbonate or citrate (black
squares), or magnesium potassium citrate (white triangles) are
plotted to three variables: Change of urinary pH, calcium, and
magnesium between values before and after treatment. The
change in urinary calcium can be numerically fitted into the
equation Ucalcium  V  0.70  0.26  (Umagnesium V) 
2.06  UpH. The R
2 for the regression was 0.58.
Figure 2. Perfusion of MgCl2, CaCl2, or vehicle in normal or
PTX rats: Effect on calcium-creatinine and magnesium-creati-
nine ratios. Normal rats (A through C) or PTX rats (D through F)
received an intravenous load of 20 mol/100 g body weight
MgCl2 (A and D) or CaCl2 (B and E) or an equivalent volume of
0.45% NaCl (vehicle; C and F) in 1 h. Urine was collected by
30-min periods and analyzed for calcium, magnesium, and
creatinine. Results are reported as calcium-creatinine (Œ) or
magnesium-creatinine (F) ratio related to the baseline value.
Each point represents the mean  SEM of values obtained
from three to eight rats.
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injected a single intravenous bolus of 10 mg/kg furosemide
at the end of the baseline collection period, just before start-
ing the MgCl2 perfusion. Figure 3A shows the effect of fu-
rosemide on calcium-creatinine ratio. The increase in cal-
cium-creatinine ratio induced by magnesium was not
different in amplitude compared with rats that did not re-
ceive furosemide, but it peaked earlier after the start of the
MgCl2 perfusion. Furosemide had no effect on the increase
in magnesium-creatinine ratio induced by magnesium, as
shown in Figure 3B.
When the same furosemide protocol was applied to PTX
rats, we still observed an increase of the calciuria after the in-
travenous magnesium load (Figure 3C), and its peak appeared
earlier comparedwith rats not injectedwith furosemide. Over-
all, our data shows that the magnesium-increased calciuria is a
phenomenon independent from PTH and is still present de-
spite inhibition of transport at the thick ascending limb. These
results point to the distal nephron as the most likely site of
magnesium-induced calciuria.
Expression in Xenopus laevis Oocytes
Because the distal tubule calcium channel TRPV5 has been
shown to be regulated bymagnesium and apical pH in absence
of calcium as permeant ion,21–25,39 we expressed TRPV5 in Xe-
nopus laevis oocytes and measured isotopic calcium uptake at
differentmagnesium concentrations (from 1 to 10mM) and at
two different pH (pH 5 and 8).When comparedwith pH 8 and
1mMmagnesium, 45calciumuptakewas decreased at pH5 and
1 mM magnesium (Figure 4). At both pH 5 and 8, calcium
uptake was significantly inhibited by increasing magnesium
concentrations in a concentration-dependent manner, reach-
ing significance at 5 and 10mM (comparedwith 1mM). There
was no difference in surface expression of TRPV5 under the
conditions of varying pH and extracellular magnesium identi-
cal to that of the calcium flux measurements, as assessed by
confocal imaging of enhanced green fluorescent protein-
tagged TRPV5 (Supplemental Figure 1). These findings indi-
cate that TRPV5 activity assessed by 45calcium uptake is inhib-
ited by both high extracellular magnesium concentration and
low extracellular pH and is likely mediated by gating of the
channel and not by changing number of channels.
DISCUSSION
Urinary magnesium and pH are
known regulators of calciuria at the
whole organism level, but the mecha-
nisms underlying this regulation have
not been unveiled yet. With these
studies, we are providing several lines
of evidence to help decipher this phe-
nomenon. First, in humans, we
showed that magnesium-induced cal-
ciuria can be influenced by changes in
urinary pH. Second, the rat data are
compatible with a distal effect of uri-
nary magnesium on renal calcium re-
absorption, independent from PTH,
pointing out the distal convoluted tu-
bule as the putative location for the
magnesium-induced calciuria. Third,
the calcium flux assay showed that
TRPV5, the apical calcium channel ex-
pressed in the distal convoluted and
the connecting tubule in the kidney, is
Figure 3. Effect of furosemide on magnesium-induced calciuria. Normal rats (A and B) or
PTX rats (C and D) were administered a unique bolus of 10 mg/kg furosemide immedi-
ately before starting to receive an intravenous load of 20 mol/100 g body weight MgCl2
in 1 h. Urine was collected by 30-min periods and analyzed for calcium, magnesium, and
creatinine. Results are presented as calcium-creatinine ratio of rats treated (gray triangles)
or not (black triangles) with furosemide or as magnesium-creatinine ratio of rats that were
treated (gray dots) or not (black dots) with furosemide, related to the baseline value. Each
point represents the mean  SEM of values obtained from four to five rats.
Figure 4. Magnesium concentration and pH modulate 45calcium
uptake in oocytes expressing TRPV5. X. laevis oocytes were in-
jected with TRPV5 cRNA and subjected to 45calcium uptake assay
with the uptake solution containing 1 to 10 mM MgCl2 at pH 5 or
8, as indicated. The results are presented as mean SEM of three
different experiments with a total of 28 to 35 oocytes per condi-
tion and are related to 1 mM MgCl2 and pH 5.
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a strong candidate for this regulatory pathway, because it
can be inhibited by both low pH and high magnesium.
Hypercalciuria is a major risk factor for nephrolithiasis.
Our results suggest that high urinary magnesium can increase
calciuria and potentially increase stone risk. Some have es-
poused the notion that magnesium is efficacious in preventing
stone formation by binding or complexing oxalate in the bowel
and urine,26,27,40,41 by inhibiting calcium oxalate crystal forma-
tion,26,42,43 and by increasing urinary citrate when given as al-
kali salt.44 In vitro studies have shown that magnesium is an
inhibitor of calcium oxalate crystal growth in artificial, rodent,
and human urine but at supraphysiologic concentra-
tions.28,45–50 In our retrospective analysis of human trials, we
showed that magnesium supplementation indeed increased
calciuria, but this effect was minimized when there was simul-
taneous alkalization of the urine. One should take caution in
any retrospective meta-analysis in that not all variables were
vigorously controlled. The impact of magnesium and pH on
calciuria can be estimated by a purely empirical equation, but
this paradigm will need further studies in a prospective, con-
trolled trial. Nonetheless, the current retrospective analysis of
pooled human studies supports the notion of magnesium–pH
interaction in regulating calciuria.
In the rat experiments, all of the animals were on normal
chow and most probably magnesium replete. Hence, it is rea-
sonable to assume that these studies examined primarily the
effect of acute changes in luminal magnesium. The effect of
changes in intracellularmagnesium, although unlikely, cannot
be ruled out with clearance studies. We attempted to deter-
mine the segment of the nephron involved in the magnesium-
induced increase in calciuria. Although we did not measure
GFR and proximal tubular calcium reabsorption directly, we
assume they did not change, on the basis of unaltered endog-
enous creatinine clearance and studies performed by oth-
ers.10,11 Previous micropuncture studies in the rat suggested
the thick ascending limb as a probable site for this regula-
tion,10,11 but this assumption was never challenged with furo-
semide to the best of our knowledge. Because disruption of
calcium reabsorption in the thick ascending limb by furo-
semide had little effect on the amplitude of the magnesium-
induced increase in calcium-creatinine ratio, we postulate that
the majority of the regulation of calciuria by magnesium takes
place in the distal convoluted tubule. Magnesium infusion
increased urinary calcium excretion in the absence of PTH
and in the presence of slight hypocalcemia, even though the
effect was less prominent than with intact parathyroids. Inhi-
bition of PTH secretion bymagnesium via the calcium-sensing
receptor (CaSR) in the parathyroid gland37,38 is unlikely to
account for the hypercalciuria. This strengthens a local renal
regulation for the rise in urinary calcium after intravenous
magnesium.
In the distal convoluted tubule and connecting tubule, cal-
cium is reabsorbed transcellularly through the apical calcium
channel TRPV5, complexed in the cytoplasmic compartment
by the calbindin system, and extruded to the interstitium by
the sodium/calcium exchanger and the calcium ATPase.51
TRPV5 is critical in that process, and its deletion in the mouse
leads to pronounced hypercalciuria.43 TRPV5 is regulated by
numerous calcitropic hormones but also by its own trans-
ported substrate.52 As intracellular calcium concentration
rises, TRPV5 open probability decreases drastically. Thus, in
electrophysiologic studies, sodium is used as surrogate per-
meant ion. Using whole-cell configuration, Vennekens et al.21
showed that monovalent sodium currents through TRPV5
were inhibited by increasing magnesium concentration, with
Ki in the micromolar range, and that this inhibition was pH
dependent. Here, we used calcium as permeant cation of
TRPV5 and measured actual calcium flux instead of sodium
current in the heterologous X. laevis oocyte expression system.
We showed that millimolar concentrations of magnesium in-
hibits calcium uptake in a pH-dependent manner. This range
of concentration is more compatible with urinary magnesium
concentrations, usually in the order of 1 to 10 mM.
Taken together, our data support that TRPV5 is an impor-
tant player in the magnesium-elicited increase of calciuria;
however, it does not exclude additional mechanisms for this
inhibition of calcium reabsorption.53 The role of the renal
CaSR will have to be defined by additional experiments. Mag-
nesium is known to bind to the CaSR andmay inhibit calcium
reabsorption in the thick limb. In a distal convoluted tubule
cell line, Bapty et al.54 showed that CaSR is sensitive to extra-
cellular magnesium in physiologic concentrations.
In conclusion, this study provides a translational ap-
proach to a phenomenon described almost one century
ago and sheds light on the putative site of action of mag-
nesium on calcium reabsorption and its molecular basis.
Speculations about the clinical significance of varying urinary
pH in patients on magnesium supplementation await further
investigations.
CONCISE METHODS
Human Data Analysis
Retrospective clinical datawere obtained from theUniversity of Texas
Southwestern Medical Center Nephrolithiasis Registry using 17
source documents from 12 previous publications that dealt with
physiologic and physicochemical effects of various magnesium and
potassium salts.17,26–36 Key data retrieved for this communication
were 24-h urinarymagnesium, pH, and calcium. In seven source doc-
uments, all key data had already been published26–29,35; in the remain-
ing 10 source documents, one or more key data had not been previ-
ously published.
The source documents from 17 treatment trials were divided into
three groups according to the type of intervention (Table 1): Magne-
sium oxide (MgO) or magnesium citrate (Mg3Citrate2; group 1), po-
tassium bicarbonate (KHCO3) or potassium citrate (K3Citrate; group
2), and potassium-magnesium citrate (K4MgCitrate2; group 3). Dur-
ing treatment, participants were kept on a constant metabolic diet in
11 trials17,26–29,33,35 and on instructed diet with a similar intake of
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magnesium, potassium, and calcium in remaining six trials.30–32,34,36
The 17 source documents represented trials of 1 mo in duration.
Although we had reported on trials of longer duration, they were not
included here because of problems in long-term dietary adherence
and concern for development of secondary compensatory physiologic
changes. Participants were normal volunteers or patients who had
kidney stones and did not have evidence of magnesium depletion or
hypomagnesemia, disturbance in acid-base balance, or abnormal se-
rum potassium or calcium concentrations. Endogenous creatinine
clearance was 0.6 ml/min per kg. In six trials, participants were
normal individuals who had taken hydrochlorothiazide 50 mg/d
alone for 1 to 3 wk, together with potassium citrate, potassium-mag-
nesium citrate, or magnesium citrate for 3 wk.30–32,36 Serum magne-
sium concentration remained unchanged with potassium citrate
treatment and increased slightly within normal limits when magne-
sium salts were co-administered with thiazide. In the remaining 11
trials, only the test potassium or magnesium salts were given.
Group 1 (MgO or Mg3Citrate2) comprised two trials with MgO
and two with Mg3Citrate2 (Table 1). One trial used a high dosage of
magnesium (82.2mEq/d) for 6 d;26 the remaining trials used a dosage
of 24.5 to 40.0 mEq/d magnesium for 2 to 3 wk.27,31 Forty-seven
individuals participated in the four trials (four to 21 per trial). In
group 2, KHCO3 was given in one trial,33 and K3Citrate was given in
seven trials.17,28,29,31,33–35 Eighty-nine participants (five to 21 per trial)
received potassium alkali at a dosage of 40 to 80 mEq/d for 1 to 4 wk.
Group 3 comprised five trials with K4MgCitrate2.28,30–32,36 This alka-
line salt of potassium andmagnesiumwas given at a dosage of 42 to 49
mEq/d potassium, 21.0 to 24.5 mEq/d magnesium, and 63.0 to 73.5
mEq/d citrate for 1 to 3 wk. A total of 102 individuals participated in
these trials (10 to 30 per trial).
Clearance Studies in Rats
All animal protocols were approved by the Institutional Animal Care
and Use Committee of the University of Texas SouthwesternMedical
Center. Housing and day-to-day care were in accordance with the
standards of the Guide for the Care and Use of Laboratory Animals
and the Animal Welfare Act. Normal and PTX Sprague-Dawley rats
were purchased from Charles River (Wilmington, MA), housed in
ventilated rooms with 12/12-h dark-light cycles at 22°C, and were
given free access to regular chow and water. PTX rats drank water
supplemented with 1% (wt/vol) calcium citrate to helpmaintain nor-
mocalcemia. Rats (230 to 280 g) were anesthetized with a cocktail of
intraperitoneal ketamine, xylazine, and acepromazine (50, 5, and 1
mg/kg body wt, respectively). Femoral veins were identified on both
sides, and P50 tubing was used to cannulate the right vein. A 0.45%
saline solution was started at 4 ml/h per 100 g body wt. The bladder
was exposed by a midline incision, and a PE205 catheter was intro-
duced to collect urine. After a 30-min stabilization period, bladder
urine was discarded and baseline urine was collected for 30 min. The
intravenous perfusion was then switched to either 5 mM CaCl2 or 5
mM MgCl2 in 0.45% saline or maintained at 0.45% saline as the ve-
hicle control, at the same perfusion rate for 1 h. The total calcium or
magnesium load was 20 mol/h per 100 g body wt. At the end of the
calcium or magnesium load, perfusion was switched back to 0.45%
saline and continued for an additional hour. Urine was collected in
30-min periods. When indicated, furosemide (Furosemide Injection
USP; American Regent Laboratories Inc., Shirley, NY) or control ve-
hicle was given as a single bolus (10 mg/kg body wt) after the baseline
collection and before the start of the calcium or magnesium load.
Blood was drawn at baseline, at the end of the calcium or magne-
sium load, and at the end of the experiment from the left femoral vein.
Urinary calcium, magnesium, and creatinine levels were analyzed by
the Mineral Metabolism Core Laboratory of our center. Calcium and
magnesium were assayed by atomic absorption using a Varian Spec-
trAA 220 instrument, and creatinine was assessed using the Roche
kinetic alkaline picrate kit run on a Roche (Indianapolis, IN) COBAS
MIRA autoanalyzer. Plasma sodium, calcium, magnesium, albumin,
and creatinine were measured by the Core Laboratory of our Center
using a Beckman CX9ALX (Beckman Coulter, Fullerton, CA).
Expression in X. laevis Oocytes
Stage 5 to 6 oocytes were surgically removed from X. laevis females,
isolated by collagenase digestion, and kept at 19°C inmodified Barth’s
saline (MBS; 90 mM NaCl, 1 mM KCl, 0.41 mM CaCl2, 0.33 mM
CaNO3, and 0.82 mM MgSO4) supplemented with penicillin (100
U/ml) and streptomycin (100 mg/ml).55 Capped cRNA was prepared
from 1 g of BamH1-linearized cDNA of the rabbit TRPV5 cDNA
with the T7 mMessage mMachine kit (Ambion Inc., Austin, TX).
Complementary RNA integrity was visualized on ethidium bromide–
stained agarose gel for quality and quantified by spectrophotometry.
Five nanograms of cRNA (in 50 nl of water) or equivolume of water
for control was injected per oocyte with aNanoject II injector (Drum-
mond Scientific Co., Broomall, PA).
After incubation in regular MBS for 48 h and in MBS without
calcium 6 h before the assay, uptake of 45calcium was performed for
1 h at room temperature with gentle occasional shaking. Uptake so-
lution contained 90mMNaCl, 0.1mMCaCl2, 1mCi/ml
45CaCl2, 1 to
10 mM MgCl2 as indicated, and 10 mM HEPES (pH 5 or 8 as indi-
cated). It is noteworthy that in the complete absence of magnesium,
therewas a large and variable background calciumuptake attributable
to some endogenousmagnesium-sensitive calcium conductances. Af-
ter extensive washing (6) with ice-cold stop solution (in mM: 90
NaCl, 0.5 CaCl2, 1 MgCl2, 5 HEPES, 1.5 LaCl3), oocytes were dis-
solved in 200 l of 10% SDS and counted individually in scintillation
liquid on an LS 3801 Beckman Counter (Beckman Instruments). The
data are presented as mean  SEM of 28 to 35 oocytes from three
different experiments and were normalized to the mean obtained
from uptake performed at pH 5 and 1 mMMgCl2.
For semiquantitative assay of surface TRPV5, oocytes were in-
jected with either water or enhanced green fluorescent protein-
TRPV5 cRNA and subjected to a regular calcium uptake assay (1 h)
but without 45calcium (only cold). Oocytes were immediately fixed in
3% PFA, washed in PBS, frozen in liquid nitrogen, and cut at 6-m
sections on a cryostat. Sections were thawed, dried, and rehydrated
directly in the mounting medium. Images were acquired on a Leica
(Heerbrugg, Switzerland) SP5 confocal microscope using an argon
laser and the same setup gain and offset for each condition (magnifi-
cation20).Water-injected oocytes gave just a negligibly faint halo of
autofluorescence.
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Statistical Analysis
Weperformed univariate within-group and across-group evaluations
of changes in urinary calcium, magnesium, and pH as well as a mul-
tivariate assessment of the relationship of those three variables. The
within-group analysis used paired t test. The univariate across-group
analysis of mean changes was accomplished with a one-way ANOVA
followed by a post hoc comparison of the mean changes using the
Student-Newman-Keulsmultiple range test. A linear regression of the
change in urinary calcium onto the associated changes in urinary
magnesium and pH was used to capture the relationship of those
three variables. The statistical analyses were implemented in the SAS
9.1 statistical software package (SAS Institute, Cary, NC). For each
statistical test, an observed significance (P value) 0.05 was consid-
ered to be statistically significant. In all analyses, observations were
weighted by the number of participants per trial.
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